Mylan Plaintiffs Make New Bid For Treble Damages

Law360, New York (November 5, 2007, 12:00 AM EST) -- In its long-running antitrust litigation against Mylan Laboratories over two of the generic drug maker's anti-anxiety drugs, Blue Cross Blue Shield of Massachusetts has renewed its effort to push the court to triple damages against Mylan and two drug ingredient supplier defendants, citing details from a separate case.

In court documents filed Wednesday in the U.S. District Court for the District of Columbia, BCBS Massachusetts contends that a separate malpractice suit Mylan brought against its former antitrust counsel Eliot G. Disner, provides key information that supports...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.